Melanoma DNA vaccine - PowderJect

Drug Profile

Melanoma DNA vaccine - PowderJect

Latest Information Update: 20 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PowderJect Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 20 May 2004 No development reported - Phase-I for Malignant melanoma in USA (Intradermal)
  • 24 Oct 2001 A study has been added to the Cancer immunogenicity section
  • 11 Aug 2000 Preliminary results from a phase I trial have been added to the adverse events section and the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top